Samsung Group saw its market capitalization fall more than 56 trillion won (US$49.47 billion) this year due to the fall in both electronics and biotech shares.
According to Seoul-based financial data provider FnGuide on Nov. 18, the combined market value of Samsung Group's 16 listed affiliates came to 418.33 trillion won (US$369.55 billion) as of Nov. 14, down 56.8 trillion won (US$50.18 billion), or 11.95 percent from 475.13 trillion won (US$419.72 billion) at the end of last year.
In particular, market bellwether Samsung Electronics Co. lost 45.85 trillion won (US$40.5 billion), or 13.94 percent, of its market value from 328.94 trillion won (US$290.59 billion) to 283.09 trillion won (US$250.08 billion).
This was largely due to concerns over an expected slowdown in semiconductor sales from a fizzling-out in the memory boom. Samsung BioLogics Co., which ranked among the top 10 in terms of market capitalization along with Samsung Electronics, also saw its market value fall to 22.13 trillion won (US$19.55 billion), down 2.41 trillion won (US$2.13 billion), or 9.84 percent, from 24.55 trillion won (US$21.68 billion) during the period.
The biopharmaceutical company’s stock has been suspended from trading on the main Seoul bourse from the closing on Nov. 14 after the Securities & Futures Commission concluded that it deliberately violated accounting rules. Samsung BioLogics ranked fifth in terms of market capitalization at the time but dropped to seventh place as of the 16th.
Samsung Life Insurance Co. lost the largest of 26.35 percent in market value, followed by Samsung Securities Co., which sparked a “ghost stock” blunder in April, with 20.49 percent and Samsung C&T Corp. with 16.27 percent.
Meanwhile, Samsung Heavy Industries Co., the world's third-biggest shipbuilder by sales, gained 56.69 percent in market value this year, with some companies showing an increasing trend.